Literature DB >> 15950755

In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.

E M Torres1, C Monville, P R Lowenstein, M G Castro, S B Dunnett.   

Abstract

We have investigated the in vivo dynamics of an adenovirus-based, LacZ expressing vector, RAd36, at different doses, when injected unilaterally into the corpus striatum of normal rats. We have further investigated the characteristics of this vector in the presence of a 6-OHDA lesion of the nigrostriatal pathway. The dopamine-depleting lesion had an effect on both the number and the distribution of cells transduced by the adenoviral vector. The lesioned side of the brain contained significantly greater numbers of beta-galactosidase positive cells than the unlesioned side at 3 days, 1 week and 4 weeks post-injection and the distribution of transduced cells was altered by the presence of a dopamine lesion. We conclude that the increased levels of transgene expression seen in the lesioned hemisphere are due to a change in the diffusion characteristics of the injected vector in the lesioned hemisphere. These results indicate that, when investigating the use of virus-based vectors, ultimately for use in gene therapies in the CNS, the in vivo dynamics of the vector need to be assessed not only in the normal brain, but also in the pathological brain state such as animal models of target diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950755      PMCID: PMC2902248          DOI: 10.1016/j.molbrainres.2004.10.046

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  32 in total

1.  An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.

Authors:  A I Kuzmin; O Galenko; R C Eisensmith
Journal:  Mol Ther       Date:  2001-03       Impact factor: 11.454

2.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

Review 3.  High-capacity 'gutless' adenoviral vectors.

Authors:  S Kochanek; G Schiedner; C Volpers
Journal:  Curr Opin Mol Ther       Date:  2001-10

Review 4.  Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.

Authors:  K Jooss; N Chirmule
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

5.  Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.

Authors:  B Connor; D A Kozlowski; J R Unnerstall; J D Elsworth; J L Tillerson; T Schallert; M C Bohn
Journal:  Exp Neurol       Date:  2001-05       Impact factor: 5.330

6.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials.

Authors:  R A Dewey; G Morrissey; C M Cowsill; D Stone; F Bolognani; N J Dodd; T D Southgate; D Klatzmann; H Lassmann; M G Castro; P R Löwenstein
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

7.  Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging.

Authors:  F Cicchetti; A L Brownell; K Williams; Y I Chen; E Livni; O Isacson
Journal:  Eur J Neurosci       Date:  2002-03       Impact factor: 3.386

8.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain.

Authors:  C E Thomas; D Birkett; I Anozie; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

Review 9.  Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.

Authors:  A Björklund; D Kirik; C Rosenblad; B Georgievska; C Lundberg; R J Mandel
Journal:  Brain Res       Date:  2000-12-15       Impact factor: 3.252

10.  Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.

Authors:  J F Hamilton; P F Morrison; M Y Chen; J Harvey-White; R S Pernaute; H Phillips; E Oldfield; K S Bankiewicz
Journal:  Exp Neurol       Date:  2001-03       Impact factor: 5.330

View more
  1 in total

1.  Mitochondrial imaging in dorsal root ganglion neurons following the application of inducible adenoviral vector expressing two fluorescent proteins.

Authors:  Payman Nasr; Patrick G Sullivan; George M Smith
Journal:  J Neurosci Methods       Date:  2008-05-03       Impact factor: 2.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.